ESMO 2018 – Reduced mortality, relapses for sarcoma patients in French reference centre


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An analysis of 47,023 patients shows that those diagnosed and treated within NetSarc, the French clinical reference network for soft tissue and visceral sarcomas, received a much higher quality of initial and final resections of their tumours.
  • Surgery within NetSarc was also a strong predictor of relapse-free survival and overall survival.

Why this matters

  • Sarcomas are both rare and varied tumours.
  • This analysis quantifies how much patients profit from treatment in specialised centres or networks and could serve as a rationale for mandatory referral.

Key results

  • While 76% of patients at NetSarc had either sarcoma (57%), tumours of intermediate malignancy (13.3%) or GIST (5.7%), lesions were found to be benign in 20.8%, and a further 4.1% had nonmesenchymal malignant tumors or other/unknown diagnoses (3.1%/0.7%).
  • Quality of initial resection outside/within NetSarc for R0 15.9% vs 53.0%; R1 16% vs 24.0%; R2 8.5% vs 4.2%; unknown 59.1% vs 18.8%.
  • Quality of final resection outside/within NetSarc for R0 24% vs 56.7%; R2 12.8% vs 21.8%; R2 5.0% vs 3.0%; unknown 58.2% vs 18.5%.
  • For those with surgery in NetSarc, the relative risk for relapse-free survival was 0.556 and for overall survival 0.637 in comparison to patients outside NetSarc.

Limitations

  • Incomplete data for a high proportion rate of patients regarding date of surgery and initial/final quality of resection.

Expert opinion

  • “Mandatory treatment of sarcoma patients seems to be the simplest and cheapest way to improve survival in these orphan tumors.” Jean-Yves Blay, principal investigator, the NETSARC network.

Funding

  • French NCI (INCa).

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit